Increasing Prevalence of Hay Fever among the Population and Rising Awareness about Allergic Rhinitis are Expected to Boost the Growth of the Global Allergic Rhinitis Market at a CAGR of 3.30% During the Forecast Period of 2022 to 2030

Pune, India, October 2022, MRFR Press Release/- Market Research Future has published a Cooked Research Report on the Global Allergic Rhinitis Market.

Market Highlights

Allergic Rhinitis Market is expected to register a CAGR of 3.30% during the forecast period with a market value of USD 18.02 billion till 2030.

Allergic rhinitis is an inflammation of the nose caused by inhaling allergens such as pollen or dust. Allergic rhinitis, also known as hay fever, is a type of inflammation which occurs due to the allergic response to specific allergens in the air. Allergic rhinitis treatment includes medications such as corticosteroids, antihistamines, nasal sprays, and leukotriene modifiers.

The rising prevalence of allergic rhinitis, growing government initiatives to promote awareness regarding allergic rhinitis, and increasing healthcare expenditure and expansion of the private healthcare is likely to drive the growth of the global allergic rhinitis market during the forecast period.

Segment Analysis

The Global Allergic Rhinitis Market, by type, has been segmented into seasonal allergic rhinitis, perennial allergic rhinitis, and occupational allergic rhinitis.

Based on treatment, the global allergic rhinitis market has been divided into antihistamines, corticosteroids, decongestants, immunotherapy, intranasal anticholinergics, and others.

The global allergic rhinitis market, by route of administration, has been segmented into nasal, oral, and others.

The global allergic rhinitis market, by distribution channel segments, has been classified into retail pharmacies, hospital pharmacies, and online stores.

Browse Full Report Details @ https://www.marketresearchfuture.com/reports/allergic-rhinitis-market-1547

Regional Analysis

The Global Allergic Rhinitis Market, based on region, has been divided into the Americas, Europe, Asia-Pacific, and the Middle East & Africa.

The Americas is likely to hold the largest share of the global allergic rhinitis market. The Americas is divided into North America and Latin America. North America has been further subdivided into the US and Canada. The strategic acquisitions by major players to enhance product portfolio, increasing cases of respiratory disorders, the existence of major market players in the region, and the availability of advanced medications for the treatment of allergic rhinitis are expected to drive the market growth in this region.

The Europe market established substantial growth in the market owing to the rising adoption of advanced treatment by hospitals and patients in the European countries, and the continuous efforts made by Global Allergy and Asthma European Network to strengthen European research, spread excellence.

Asia-Pacific is estimated to be the fastest-growing region in the global market due to the continuous developments in developing countries like India and China Additionally, rising investments by major players in the market in the Asia-Pacific region is likely to drive the growth of the market.

The allergic rhinitis market in the Middle East & Africa is expected to grow due to the rising awareness about allergic rhinitis coupled with increasing collaborations and agreements to commercialize allergic rhinitis products.

Key Players

MRFR recognizes the following companies as the Key Players in the Global Allergic Rhinitis Market—

Novartis AG, Meda Pharmaceuticals, AstraZeneca, GlaxoSmithKline plc, Johnson & Johnson Services, Inc, Bayer AG, Sanofi, Boehringer Ingelheim, Merck & Co., ALK-Abelló A/S, and others.

Key Findings of the Study

• The Global Allergic Rhinitis Market is estimated to grow at USD 15064.12 Million by 2025 at a CAGR of 3.10% during the assessment period.


• Americas accounted for the largest share of the global market due to the presence of key market players and the increasing prevalence of hay fever in the US and Canada.


• Based on type, the Seasonal Allergic Rhinitis segment accounted for the largest market share of 4% in 2018.


• Based on treatment, the antihistamines segment accounted for the largest market share of 4% in 2018.


• On the basis of route of administration, the nasal segment accounted for the largest market share of 1% in 2018.


• Based on distribution channel, the retail pharmacies segment held a market share of 53.5% in 2018.

Browse In-depth Market Details [Table of Content, List of Figures, List of Tables] of Allergic Rhinitis Market Research Report